Marginal zone lymphoma

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

1 event
Apr 2024Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

International Extranodal Lymphoma Study Group (IELSG)

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for Marginal zone lymphoma.
Check the disease page for updates →

Approved Treatments

2 FDA-approved

Ukoniq

(umbralisib)Orphan drugstandard

TG Therapeutics, Inc.

BRUKINSA

(zanubrutinib)Orphan drugaccelerated

BeOne Medicines USA, Inc.

Kinase Inhibitor [EPC]

12.1 Mechanism of Action Zanubrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). Zanubrutinib forms a covalent bond with a cyste...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

1 active trial
1Unknown
1Total recruiting
Search clinical trials for Marginal zone lymphoma

Recent News & Research

No recent news articles indexed yet for Marginal zone lymphoma.
Search PubMed for Marginal zone lymphoma

Browse all Marginal zone lymphoma news →

Specialist Network

Top 6 by expertise

View all Marginal zone lymphoma specialists →

Quick Actions